| 摘要 |
The disclosure includes protocols for activating and administering human blood cells to cancer patients, severely myelosuppressed patients, including severely myelosuppressed patients treated for cancer, e.g., by chemotherapy or radiation. The protocol may include culturing blood cells in the presence of activating agents, for example, a cytokine and an ionophore. |
